Patents by Inventor Holger Siebeneicher
Holger Siebeneicher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240239804Abstract: The present invention covers furoindazole compounds of general formula (I): in which R1, R2, R3, R4, R5, R6, R7a and R7b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetesType: ApplicationFiled: April 25, 2022Publication date: July 18, 2024Inventors: Olaf PANKNIN, Frank SACHER, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Holger SIEBENEICHER
-
Patent number: 12006303Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: July 20, 2022Date of Patent: June 11, 2024Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Patent number: 12006304Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: July 20, 2022Date of Patent: June 11, 2024Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Publication number: 20230174508Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: July 20, 2022Publication date: June 8, 2023Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Publication number: 20230112499Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and poType: ApplicationFiled: December 14, 2020Publication date: April 13, 2023Applicant: Bayer AktiengesellschaftInventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
-
Publication number: 20220388982Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: July 20, 2022Publication date: December 8, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Publication number: 20220241261Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.Type: ApplicationFiled: December 7, 2021Publication date: August 4, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
-
Patent number: 11319324Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 18, 2018Date of Patent: May 3, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
-
Publication number: 20210317128Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 18, 2018Publication date: October 14, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
-
Publication number: 20210053941Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: September 1, 2020Publication date: February 25, 2021Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Patent number: 10793545Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: April 5, 2019Date of Patent: October 6, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Publication number: 20200085791Abstract: The present invention covers [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1H-1,2,3-triazol-5-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200087284Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200079758Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20190388410Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.Type: ApplicationFiled: May 31, 2019Publication date: December 26, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
-
Patent number: 10442772Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: March 16, 2018Date of Patent: October 15, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
-
Patent number: 10435396Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: February 28, 2017Date of Patent: October 8, 2019Assignee: Bayer Pharma AktiegesellschaftInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Judith Günther, Holger Steuber, Ulf Bömer, Martin Lange, Reinhard Nubbemeyer, Nicholas Charles Ray, Pascal Savy
-
Publication number: 20190233395Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: April 5, 2019Publication date: August 1, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Patent number: 10308634Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: November 25, 2015Date of Patent: June 4, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Publication number: 20190071432Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: February 28, 2017Publication date: March 7, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Judith GÜNTHER, Holger STEUBER, Ulf BÖMER, Martin LANGE, Reinhard NUBBEMEYER, Nicholas Charles RAY, Pascal SAVY